Table 1.
Baseline characteristics of the population (white, non-Hispanic, adult females, N=236)
| Patient demographic and clinical characteristics | |
| Age at enrollment, median years (IQR) | 53 (46–60) |
| Diabetes mellitus, n (%) | 99 (42%) |
| BMI, median kg/m2 (IQR) | 36 (31–40) |
| Waist to hip ratio, median (IQR) | 0.91 (0.86–0.95) |
| Laboratory measures, median (IQR) | |
| ALT, U/L | 51 (31–76) |
| AST, U/L | 42 (28–60) |
| HbA1c, % | 5.9 (5.5–6.6) |
| Triglycerides, mg/dL | 152 (112–202) |
| Total cholesterol, mg/dL | 196 (172–224) |
| HDL cholesterol, mg/dL | 46 (38–53) |
| LDL cholesterol, mg/dL | 122 (96–145) |
| Serum glucose, mg/dL | 98 (88–119) |
| Serum insulin, μU/mL | 17 (11–26) |
| Histologic characteristics | |
| Steatosis, n (%) | |
| <5% | 11 (5%) |
| 5–33% | 101 (43%) |
| 34–66% | 76 (32%) |
| >66% | 48 (20%) |
| Lobular inflammation, n (%) | |
| 0 | 1 (<1%) |
| <2 under 20x mag | 125 (53%) |
| 2–4 under 20x mag | 78 (33%) |
| >4 under 20x mag | 32 (14%) |
| Ballooning, n (%) | |
| None | 83 (35%) |
| Few | 44 (19%) |
| Many | 109 (46%) |
| Fibrosis, n (%) | |
| None | 57 (24%) |
| Mild, zone 3, perisinusoidal | 22 (9%) |
| Moderate, zone 3, perisinusoidal | 20 (9%) |
| Zone 3 and periportal, any combination | 43 (18%) |
| Bridging | 51 (22%) |
| Cirrhosis | 34 (15%) |
| NASH diagnosis, n (%) | |
| No NASH | 54 (23%) |
| Suspicious/borderline/indeterminate: Zone 3 or Zone 1 | 52 (22%) |
| Yes, definite | 129 (55%) |
| NAS (range 0–8), median (IQR)† | 4 (3–6) |
†
NAS is the NAFLD Activity Score, a sum of scores for steatosis, lobular inflammation, and ballooning.